Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?

Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?

CAR-T cells therapy can give rise to most common and concerning two side effects – cytokine release syndrome (CRS) and neurotoxicity. But in our CD19 CAR-T cells therapy clinical trial, we observed 1 out of 17 patients with B-cell acute lymphoblastic leukemia (B-ALL) developed acute myelofibrosis(AM...

Full description

Bibliographic Details
Main Authors: Xun Lai, Yun Yan Sun, Lung Ji Chang, Yu Ru Ma, Xue Zhong Gu, Xiang Mei Yao, Bo Nie, Yan Wen, Xue Mei Zhang, Ya Xian Jiang, Hui Yang, Li Qun Yu, Ming Jing Fang, Ling Wang, Xue Yuan Bo
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Bioengineered
Subjects:
car-t
crs
bmf
amf
b-all
Online Access:http://dx.doi.org/10.1080/21655979.2020.1791597

Internet

http://dx.doi.org/10.1080/21655979.2020.1791597

Similar Items